CoChat

Sexually Transmitted Infections Treatment Guidelines, 2021

Open access

The DOI matches its Crossref record; 1,459 of the 1,505 references it cites were found in a registry or an index; 371 of the 802 sources its claims cite were checked for support.

Abstract

These guidelines for the treatment of persons who have or are at risk for sexually transmitted infections (STIs) were updated by CDC after consultation with professionals knowledgeable in the field of STIs who met in Atlanta, Georgia, June 11-14, 2019. The information in this report updates the 2015 guidelines. These guidelines discuss 1) updated recommendations for treatment of Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis; 2) addition of metronidazole to the recommended treatment regimen for pelvic inflammatory disease; 3) alternative treatment options for bacterial vaginosis; 4) management of Mycoplasma genitalium; 5) human papillomavirus vaccine recommendations and counseling messages; 6) expanded risk factors for syphilis testing among pregnant women; 7) one-time testing for hepatitis C infection; 8) evaluation of men who have sex with men after sexual assault; and 9) two-step testing for serologic diagnosis of genital herpes simplex virus. Physicians and other health care providers can use these guidelines to assist in prevention and treatment of STIs.

Overview

CoChat Summary

TL;DR

These CDC guidelines update the 2015 STI treatment recommendations after expert consultation and systematic literature review, covering prevention, diagnosis, treatment, and special populations. They include updated guidance for gonorrhea, chlamydia, trichomoniasis, pelvic inflammatory disease, bacterial vaginosis, *Mycoplasma genitalium*, HPV vaccination, syphilis screening in pregnancy, hepatitis C testing, sexual assault evaluation, and HSV serology.

Key findings

  • Congenital syphilis in the United States increased from 8.4 to 48.5 cases per 100,000 births during 2012–2019, a 477.4% increase.
  • Three randomized controlled trials in sub-Saharan Africa found male circumcision reduced HIV acquisition among men by 50%–60%; HPTN 052 found ART for the infected partner decreased HIV transmission to uninfected heterosexual partners by 96%.
  • Doxycycline postexposure prophylaxis after unprotected anal sex among MSM and transgender women reduced incident chlamydia and syphilis by 70% and 73%, respectively, but had no effect on gonorrhea.
  • Expedited partner therapy trials showed reductions in chlamydia prevalence at follow-up of approximately 20% and gonorrhea of approximately 50%.

Methods

  • CDC staff worked with subject matter experts to identify key questions and conduct systematic MEDLINE-based literature reviews for each section of the 2015 guidelines, focused on microbiologic eradication, symptom alleviation, prevention of sequelae, and prevention of transmission.
  • Experts presented literature assessments at an in-person meeting in Atlanta, Georgia, June 11–14, 2019; evidence was rated high, medium, or low using USPSTF-style ratings, and draft recommendations underwent peer review and a public webinar before finalization.
  • Recommendations for HIV, hepatitis C, cervical cancer screening, STI screening in pregnancy, HPV testing, and HAV/HBV vaccination were developed after reviewing existing published recommendations.

Limitations

  • The paper states these guidelines are “a source of clinical guidance rather than prescriptive standards” and that providers should consider each person’s clinical circumstances and local disease prevalence.
  • The paper states several evidence gaps, including limited data on doxycycline STI prophylaxis, no long-term data on STI postexposure prophylaxis effects on antimicrobial resistance and the microbiome, and insufficient data to recommend routine anal cancer screening with anal cytology.
  • Evident from the text: many recommendations, especially for syphilis treatment, rely on decades of clinical experience and observational data rather than randomized controlled trials; the document is a broad guideline rather than a single primary study with a defined sample or comparator.

Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.15585/mmwr.rr7004a1

Cites

1459 of 1459 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

FIGURE Algorithm to evaluate the need for nonoccupational HIV postexposure prophylaxis among adult and adolescent survivors of sexual assault Abbreviation: PEP = postexposure prophylaxis.
FIGURE Algorithm to evaluate the need for nonoccupational HIV postexposure prophylaxis among adult and adolescent survivors of sexual assault Abbreviation: PEP = postexposure prophylaxis.CC0 · PubMed Central

Verification

Claims the paper makes

221 Valid · 41 Not valid · 158 Not checked · 82 Own results and interpretations

264 more claims · 126 with their cited sources checked

Create a free account to see all 502 claims and to verify the 10 references still open.

See all claims — free account
  • Probably not a substantial claim. 72
  • It may state two separate claims as one. 188

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 1,459 references

Research works printed but not linked: 12

  1. Golden MR, Kerani RP, Stenger M, Effect of expedited partner therapy (EPT) on chlamydial prevalence: the Washington State Community-Level Trial. Presented at the STD Prevention Conference, Minneapolis, MN; March 12–15, 2012.
  2. Benton S, Smith J, Wang F, Heitgerd J, Belcher L, Patel H. HIV testing, diagnosis, and linkage to care among persons tested in select CDC-funded health care and non-health care settings, 2012–2017. Presented at the National HIV Prevention Conference, Atlanta, GA: March 18–21, 2019.
  3. Briggs GC. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 11th ed. Philadelphia, PA: Wolters Kluwer; 2017.
  4. Blanco JL, Fuertes I, Bosch J, Effective treatment of lymphogranuloma venereum (LGV) with 1g azithormycin administered weekly for 3 weeks in HIV-infected population. Presented at the Conference on Retroviruses and Opportunist Infections, Seattle, WA; February 23–26, 2015.
  5. Rolfs, 1997, A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection., N Engl J Med, 337, 307, 10.1056/NEJM199707313370504 · DOI · Paper page
  6. Ahmed, 2012, Clinical outcome in the use of cephalosporins in pediatric patients with a history of penicillin allergy., Int Arch Allergy Immunol, 158, 405, 10.1159/000333553 · DOI · Paper page
  7. Park, 2011, Screening for syphilis with the treponemal immunoassay: analysis of discordant serology results and implications for clinical management., J Infect Dis, 204, 1297, 10.1093/infdis/jir524 · DOI · Paper page
  8. Muzny, 2014, Added benefit of nucleic acid amplification testing for the diagnosis of Trichomonas vaginalis among men and women attending a sexually transmitted diseases clinic., Clin Infect Dis, 59, 834, 10.1093/cid/ciu446 · DOI · Paper page
  9. Sobel, 2001, Tinidazole therapy for metronidazole-resistant vaginal trichomoniasis., Clin Infect Dis, 33, 1341, 10.1086/323034 · DOI · Paper page
  10. Perkins, 2020, 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors., J Low Genit Tract Dis, 24, 102, 10.1097/LGT.0000000000000525 · DOI · Paper page
  11. Al Jaff, 2018, Comparison of the effectiveness of sulphur ointment, permethrin and oral ivermectin in treatment of scabies., Res J Pharm Biol Chem Sci, 9, 670
  12. Chiu S, Argaez C. Ivermectin for parasitic skin infections of scabies: a review of comparative clinical effectiveness, cost-effectiveness, and guidelines. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; 2019. https://www.ncbi.nlm.nih.gov/books/NBK545083/

Cited by

See all 3,018

Metadata

Authors
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A.
Affiliations
  • Emory University (US)
  • National Center for HIV/AIDS Viral Hepatitis STD and TB Prevention (US)
  • Brown University (US)
  • University of Washington (US)
  • University of Alabama at Birmingham (US)
  • Johns Hopkins University (US)
  • Washington University in St. Louis (US)
Corresponding author
Workowski, Kimberly A.
Venue
MMWR. Recommendations and Reports
Published
2021-07-23
Volume
70
Issue
4
Pages
1-187
ISSN
  • 1057-5987 (ISSN-L)
  • 1545-8601
OpenAlex
W3185444663
Cited by
3,018
References
1,505
Citations by year
2026: 740 · 2025: 655 · 2024: 606 · 2023: 558 · 2022: 385 · 2021: 64
FWCI
256.76
Type
journal article
Language
en
Open access
Licence
public-domain
Locations
  • MMWR Recommendations and Reports (publishedVersion, public-domain)
  • PubMed Central (publishedVersion, public-domain)
  • PubMed (publishedVersion)
Funders
National Institute of Mental Health (R25MH083620)
Topics
  • Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
Keywords
sexually transmitted infections, STI treatment, gonorrhea, Chlamydia trachomatis, Trichomonas vaginalis, pelvic inflammatory disease, bacterial vaginosis, Mycoplasma genitalium, HPV vaccine, HCV screening, HIV prevention
MeSH terms
Centers for Disease Control and Prevention, U.S., Humans, Sexually Transmitted Diseases, United States

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sexually Transmitted Infections Treatment Guidelines, 2021. https://app.cochat.ai/papers/10.15585/mmwr.rr7004a1
The paper
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021). Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR. Recommendations and Reports. https://doi.org/10.15585/mmwr.rr7004a1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.